Clinical Trial Update: Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of erlotinib and docetaxel in advanced hepatocellular carcinoma and biliary tract carcinomas was terminated, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Gabi Chiorean, MD | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-02-12